AraHarvest part1 Tube, PET, 100 sheet_set
- Known as:
- AraHarvest part1 Tube, PET, 100 sheet_set
- Catalog number:
- 310061
- Product Quantity:
- x 10
- Category:
- -
- Supplier:
- SPL
- Gene target:
- AraHarvest part1 Tube PET 100 sheet_set
Related genes to: AraHarvest part1 Tube, PET, 100 sheet_set
- Gene:
- PART1 NIH gene
- Name:
- prostate androgen-regulated transcript 1
- Previous symbol:
- -
- Synonyms:
- DKFZP586D0823, NCRNA00206
- Chromosome:
- 5q12.1
- Locus Type:
- RNA, long non-coding
- Date approved:
- 2009-09-28
- Date modifiied:
- 2018-05-16
Related products to: AraHarvest part1 Tube, PET, 100 sheet_set
Related articles to: AraHarvest part1 Tube, PET, 100 sheet_set
- TIGIT and PD-1 trigger distinct but interconnected immunosuppressive pathways. We investigated first-line domvanalimab (Fc-silent anti-TIGIT) plus zimberelimab (anti-PD-1) in PD-L1-high (≥50%), stage IIIB-IV NSCLC. - Source: PubMed
Publication date: 2026/02/11
Naidoo JarushkaPeters SolangeRunglodvatana YotsawajLi Jacky Yu-ChungFong Chin HengHo Gwo FuangHow Soon HinJuengsamarn JitladaGraham Julie RMarina NeyssaDang ThaoPatel DeepaHan SashaBermingham CandyJohnson Melissa L - LY01021 is a novel oral small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of various sex hormone-dependent disorders. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of LY01021, compared with the approved GnRH receptor antagonist relugolix. - Source: PubMed
Publication date: 2026/02/05
Li YafenTan HongyiXie JinlianDeng KunhongWu QianYang ShuangYang XiaoyanLi JinleiJia Xiang-LeiTong JinHuang JieYang Guo-Ping - - Source: PubMed
Publication date: 2026/01/22
Li BingLou GeZhang JiahuiCao NingYu Xi - Ischemic stroke (IS), a life-threatening disease, carries a high risk of disability and death. Reverse transcription quantitative real-time polymerase chain reaction was utilized to measure the PART1 and miR-638 expression in patients with IS and oxygen-glucose deprivation/reoxygenation (OGD/R) model. Superoxide dismutase (SOD), malondialdehyde (MDA), lactate dehydrogenase (LDH), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels were determined by enzyme-linked immunosorbent assay kit. Cell viability was assessed using the cell counting kit-8 assay. Apoptotic cells were analyzed by flow cytometry. To explore the interaction between PART1 and miR-638, luciferase reporter and RNA immunoprecipitation (RIP) assays were carried out. In patients with IS and OGD/R-treated cells, PART1 exhibited upregulation, whereas miR-638 showed downregulation; there was a negative correlation between these two molecules. Knockdown of PART1 increased cell viability, decreased apoptosis, lowered MDA, LDH, IL-6 and TNF-α levels, and increased SOD activity. PART1 negatively regulated miR-638 expression, and inhibition of miR-638 reduced the protective effect of the knockdown of PART1 on OGD/R-treated cells. This study demonstrated that knockdown of PART1 inhibits IS-induced neurological injury by regulating miR-638 expression, which promotes the understanding of IS disease and provides new options for the treatment of the disease. - Source: PubMed
Xu GuangfeiLi HewenHuang TingXu LiangLiu DanianJi Bo - - Source: PubMed
Publication date: 2025/11/19
Li ShuangjunShi RuyueLiu YankunNiu MingcongLiu ZhicunWang ZhongjuanGao JiwangCai HongdaZhou ZhuyuLi ShengnanZhao Xiuhua